#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cystic fibrosis lung Enteritis Pulmonary fibrosis Hypophosphatasia Immunodeficiency common variable Chemical burn Hyperinsulinism Porphyria non-acute Uveitis Haemophagocytic lymphohistiocytosis Von Hippel-Lindau disease Cryoglobulinaemia Eosinophilic granulomatosis with polyangiitis Transitional cell cancer of the renal pelvis and ureter Retinitis pigmentosa More trials…

    Learn about Rare Diseases

    Erdheim-Chester disease – Trials in Disease Krabbe’s disease Leukoencephalopathy – Basic Information Von Willebrand’s disease – Life with Disease Mucopolysaccharidosis II – Treatment Hereditary neuropathic amyloidosis – Treatment Medulloblastoma recurrent Ocular melanoma – Trials in Disease Epidermolysis bullosa – Treatment Langerhans cell sarcoma More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Gallium (68Ga) Chloride Aminocaproic Acid Tucidinostat Dexrazoxane Hydrochloride Ucp4 Bi 1839100 Clomifene Citrate Prucalopride Dupilumab HUMAN COAGULATION FACTOR XIII Atuliflapon ZODASIRAN Folinic Acid Glipizide Calcium Pantothenate Bp Rifabutin MAPLIRPACEPT Eletriptan Cagrilintide Bms-986458 More therapies…

    Learn about Your Condition

    Hypochromic anaemia Migraine COVID-19 Pertussis Micrographic skin surgery Osteoporosis postmenopausal Pneumococcal infection Urinary tract infection Hypocalcaemia Immune-mediated enterocolitis Hepatic cirrhosis Actinic cheilitis Ophthalmoplegia Polymyositis Meniscus injury More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Bladder cancer

  • Study of Sasanlimab with BCG or Alone for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Not Responding to BCG

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Sasanlimab
    Belgium France Germany Italy Poland Spain

  • Study on the Effectiveness of Durvalumab, Tremelimumab, and Chemotherapy in Patients with Advanced Bladder or Urinary System Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Tremelimumab
    • Carboplatin
    • Cisplatin
    Bulgaria Czechia Hungary Italy Poland Spain

  • Study on Durvalumab, Tremelimumab, and Enfortumab Vedotin for Patients with Muscle Invasive Bladder Cancer Ineligible or Refusing Cisplatin

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Tremelimumab
    • Enfortumab Vedotin
    • Durvalumab
    Austria France Germany Greece Italy The Netherlands +3

  • Study on BI 907828 for Patients with Advanced Biliary Tract, Pancreatic, Lung, or Bladder Cancer

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Biliary neoplasm
    • Lung adenocarcinoma
    • Pancreatic carcinoma
    Investigated Drugs:
    • (3S,3’S,3A’s,10A’s)-6-Chloro-3′-(3-Chloro-2-Fluorophenyl)-1′-(Cyclopropylmethyl)-6′-Methyl-2-Oxo-1,2,3′,3A’,10′,10A’-Hexahydro-1’H-Spiro[Indole-3,2′-Pyrrolo[2′,3′:4,5]Pyrrolo[1,2-B]Indazole]-7′-Carboxylic Acid
    Austria Belgium France Germany Spain

  • Study Comparing Enfortumab Vedotin and Pembrolizumab with Chemotherapy for Patients with Muscle-Invasive Bladder Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Cisplatin
    • Gemcitabine
    • Pembrolizumab
    Bulgaria Croatia Czechia France Germany Greece +6

  • Study of Pembrolizumab, Cisplatin, and Gemcitabine for Patients with Muscle-Invasive Bladder Cancer Eligible for Cisplatin Treatment

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Bladder cancer stage II
    • Bladder cancer stage III
    • Bladder cancer
    Investigated Drugs:
    • Cisplatin
    • Gemcitabine
    • Pembrolizumab
    Belgium Denmark France Germany Hungary Ireland +4
Previous Page
1 … 5 6 7 8 9
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!